Orphan drugs in development for long-chain fatty acid oxidation disorders: challenges and progress

References

• Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477–502.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Martin D, de Lonlay P, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999;100(22):2248–2253.
   Web of Science ®Google Scholar
• Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36(5):795–803.
   Web of Science ®Google Scholar
• Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study from 187 patients. Complementary data. J Inherit Metab Dis. 2014;37(1):137–139.
   Google Scholar
• Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47(11):1945–1955.
   PubMed Web of Science ®Google Scholar
• Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348(23):2304–2312.
   PubMed Web of Science ®Google Scholar
• Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17–45.
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter U, Tenenbaum T, Heusch A, Wendel U. Cardiomyopathy and pericardial effusion in infancy point to a fatty acid b-oxidation defect after exclusion of an underlying infection. Pediatr Cardiol. 2003;24(3):295–297.
   Google Scholar
• Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta. 1998;269(1):43–62.
   Web of Science ®Google Scholar
• Hoffman JD, Steiner RD, Paradise L, et al. Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl Co-A dehydrogenase deficiency. Mil Med. 2006;171(7):657–658.
   Web of Science ®Google Scholar
• Bertrand C, Largillière C, Zabot MT, Mathieu M, Vianey-Saban C. Very long chain acyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Biophys Acta. 1993;1180(3):327–329.
   Google Scholar
• Bonnet D, de Lonlay P, Gautier I, et al. Efficiency of metabolic screening in childhood cardiomyopathies. Eur Heart J. 1998;19(5):790–793.
   Google Scholar
• de Lonlay-Debeney P, Fournet JC, Bonnet D. Fatty acid beta-oxidation deficiency masquerading as fulminant myocarditis. Int J Cardiol. 1998;65(3):287–289.
   Google Scholar
• Kluge S, Kühnelt P, Block A, et al. A young woman with persistent hypoglycemia, rhabdomyolysis, and coma: recognizing fatty acid oxidation defects in adults. Crit Care Med. 2003;31(4):1273–1276.
   Web of Science ®Google Scholar
• Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem. 2001;47(7):1166–1182.
   PubMed Web of Science ®Google Scholar
• Das AM, Illsinger S, Lücke T, et al. Isolated mitochondrial long-chain ketoacyl-CoA thiolase deficiency resulting from mutations in the HADHB gene. Clin Chem. 2006;52(3):530–534.
   Web of Science ®Google Scholar
• Spiekerkoetter U, Lindner M, Santer R, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009;32(4):488–497.
   Google Scholar
• Sperk A, Mueller M, Spiekerkoetter U. Outcome in six patients with mitochondrial trifunctional protein disorders identified by newborn screening. Mol Genet Metab. 2010;101(2–3):205–207.
   Web of Science ®Google Scholar
• Sander J, Sander S, Steuerwald U, et al. Neonatal screening for defects of the mitochondrial trifunctional protein. Mol Genet Metab. 2005;85(2):108–114.
   Web of Science ®Google Scholar
• Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010;33(5):501–506.
   PubMed Web of Science ®Google Scholar
• Collins SA, Sinclair G, McIntosh S, et al. Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut. Mol Genet Metab. 2010;101(2–3):200–204.
   Google Scholar
• Prasad C, Johnson JP, Bonnefont JP, et al. Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program. Mol Genet Metab. 2001;73(1):55–63.
   Web of Science ®Google Scholar
• Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5–6):495–520.
   PubMedGoogle Scholar
• Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C(2):77–85.
   PubMed Web of Science ®Google Scholar
• Albers S, Marsden D, Quackenbush E, Stark AR, Levy HL, Irons M. Detection of neonatal carnitine palmitoyltransferase II deficiency by expanded newborn screening with tandem mass spectrometry. Pediatrics. 2001;107(6):E103.
   PubMed Web of Science ®Google Scholar
• Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology. 2003;60(8):1351–1353.
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis. 2010;33(5):527–532.
   Web of Science ®Google Scholar
• Pierre G, Macdonald A, Gray G, Hendriksz C, Preece MA, Chakrapani A. Prospective treatment in carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis. 2007;30(5):815.
   Web of Science ®Google Scholar
• Al-Sannaa NA, Cheriyan GM. Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype. Saudi Med J. 2010;31(8):931–934.
   PubMed Web of Science ®Google Scholar
• Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med. 2004;25(5–6):521–532.
   PubMedGoogle Scholar
• Lopriore E, Gemke RJ, Verhoeven NM, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr. 2001;160(2):101–104.
   Web of Science ®Google Scholar
• Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab. 2008;93(1):36–39.
   PubMed Web of Science ®Google Scholar
• Singla M, Guzman G, Griffin AJ, Bharati S. Cardiomyopathy in multiple acyl-CoA dehydrogenase deficiency: a clinico-pathological correlation and review of literature. Pediatr Cardiol. 2008;29(2):446–451.
   Google Scholar
• Spiekerkoetter U, Lindner M, Santer R, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32(4):498–505.
   Web of Science ®Google Scholar
• Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO. Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab. 2007;90(1):64–69.
   Web of Science ®Google Scholar
• Gillingham MB, Connor WE, Matern D, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2003;79(2):114–123.
   Web of Science ®Google Scholar
• Gillingham MB, Scott B, Elliott D, Harding CO. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab. 2006;89(1–2):58–63.
   Web of Science ®Google Scholar
• Pervaiz MA, Kendal F, Hegde M, Singh RH. MCT oil-based diet reverses hypertrophic cardiomyopathy in a patient with very long chain acyl-coA dehydrogenase deficiency. Indian J Hum Genet. 2011;17(1):29–32.
   Google Scholar
• Sharef SW, Al-Senaidi K, Joshi SN. Successful treatment of cardiomyopathy due to very long-chain acyl-CoA dehydrogenase deficiency: first case report from Oman with literature review. Oman Med J. 2013;28(5):354–356.
   Google Scholar
• DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23 Suppl 1:11–22.
   Google Scholar
• Primassin S, Ter Veld F, Mayatepek E, Spiekerkoetter U. Carnitine supplementation induces acylcarnitine production in tissues of very long-chain acyl-CoA dehydrogenase-deficient mice, without replenishing low free carnitine. Pediatr Res. 2008;63(6):632–637.
   Web of Science ®Google Scholar
• Bakermans AJ, van Weeghel M, Denis S, Nicolay K, Prompers JJ, Houten SM. Carnitine supplementation attenuates myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice. J Inherit Metab Dis. 2013;36(6):973–981.
   Web of Science ®Google Scholar
• Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130(Pt 8):2045–2054.
   PubMedGoogle Scholar
• Vockley J, Whiteman DA. Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul Disord. 2002;12(3):235–246.
   PubMed Web of Science ®Google Scholar
• Solis JO, Singh RH. Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc. 2002;102(12):1800–1803.
   Google Scholar
• Straussberg R, Harel L, Varsano I, Elpeleg ON, Shamir R, Amir J. Recurrent myoglobinuria as a presenting manifestation of very long chain acyl coenzyme A dehydrogenase deficiency. Pediatrics. 1997;99(6):894–896.
   Web of Science ®Google Scholar
• Bonham JR, Tanner MS, Polliu RJ, et al. Oral sodium 3-hydroxybutyrate, a novel adjunct to treatment for multiple acyl-CoA dehydrogenase deficiency. Society for the Study of Inborn Errors of Metabolism (SSIEM) 37th Annual Symposium. September 7–10, 1999; Genova, Italy. J Inherit Metab Dis. 1999;22(Suppl 1):101.
   Google Scholar
• Van Hove JL, Grünewald S, Jaeken J, et al. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet. 2003;361(9367):1433–1435.
   PubMed Web of Science ®Google Scholar
• Van Rijt WJ, Heiner-Fokkema MR, du Marchie Sarvaas GJ, et al. Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD. Pediatrics. 2014;134(4):e1224–e1228.
   PubMed Web of Science ®Google Scholar
• Gautschi M, Weisstanner C, Slotboom J, Nava E, Zürcher T, Nuoffer JM. Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy. Pediatr Res. 2015;77(1-1):91–98.
   PubMed Web of Science ®Google Scholar
• Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110(2):259–269.
   PubMed Web of Science ®Google Scholar
• Deng S, Zhang GF, Kasumov T, Roe CR, Brunengraber H. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. J Biol Chem. 2009;284(41):27799–27807.
   Web of Science ®Google Scholar
• Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006;29(2–3):332–340.
   PubMed Web of Science ®Google Scholar
• Barone AR, DeWard SJ, Payne N, Goldstein A, Vockley J. Triheptanoin therapy for inherited disorders of fatty acid oxidation. Program for Society for Inherited Medical Disorders Annual Meeting; March 31–April 3, 2012; Charlotte, NC. Mol Genet Metab. 2012;105(3):304.
   Google Scholar
• Karall D, Mair G, Albrecht U, et al. Sports in LCHAD Deficiency: Maximal incremental and endurance exercise tests in a 13-year-old patient with long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency (LCHADD) and heptanoate treatment. JIMD Rep. 2014;17:7–12.
   Google Scholar
• Schowalter DB, Matern D, Vockley J. In vitro correction of medium chain acyl CoA dehydrogenase deficiency with a recombinant adenoviral vector. Mol Genet Metab. 2005;85(2):88–95.
   Web of Science ®Google Scholar
• Conlon TJ, Walter G, Owen R, et al. Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. Hum Gene Ther. 2006;17(1):71–80.
   Web of Science ®Google Scholar
• Beattie SG, Goetzman E, Conlon T, et al. Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD. Hum Gene Ther. 2008;19(6):579–588.
   Web of Science ®Google Scholar
• Merritt JL 2nd, Nguyen T, Daniels J, Matern D, Schowalter DB. Biochemical correction of very long-chain acyl-CoA dehydrogenase deficiency following adeno-associated virus gene therapy. Mol Ther. 2009;17(3):425–429.
   Web of Science ®Google Scholar
• Keeler AM, Conlon T, Walter G, et al. Long-term correction of very long-chain acyl-coA dehydrogenase deficiency in mice using AAV9 gene therapy. Mol Ther. 2012;20(6):1131–1138.
   PubMed Web of Science ®Google Scholar
• Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360(8):838–840.
   PubMed Web of Science ®Google Scholar
• Gobin-Limballe S, Djouadi F, Aubey F, et al. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet. 2007;81(6):1133–1143.
   Web of Science ®Google Scholar
• Gobin-Limballe S, McAndrew RP, Djouadi F, Kim JJ, Bastin J. Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches. Biochim Biophys Acta. 2010;1802(5):478–484.
   Web of Science ®Google Scholar
• Yamaguchi S, Li H, Purevsuren J, et al. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay. Mol Genet Metab. 2012;107(1–2):87–91.
   Web of Science ®Google Scholar
• Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014;82(7):607–613.
   PubMed Web of Science ®Google Scholar
• Bastin J, Lopes-Costa A, Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum Mol Genet. 2011;20(10):2048–2057.
   PubMed Web of Science ®Google Scholar
• Aires V, Delmas D, Le Bachelier C, et al. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts. Orphanet J Rare Dis. 2014;9:79.
   Web of Science ®Google Scholar
• Amat di San Filippo C, Pasquali M, Longo N. Pharmacological rescue of carnitine transport in primary carnitine deficiency. Hum Mutat. 2006;27(6):513–523.
   Web of Science ®Google Scholar
• Rare Clinical Diseases Research Network: Initiative of the National Center for Advancing Translational Sciences (NCATS) [homepage on the Internet]. Bethesda, MD: National Institutes of Health; 2015. Available from: http://www.rarediseasesnetwork.org. Accessed February 28, 2015.
   Google Scholar
• Seminara J, Tuchman M, Krivitzky L, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab. 2010;100 Suppl 1:S97–S105.
   Google Scholar